Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials

Clinical Drug Investigation

Volumn 37, Issue 6, 2017, Pages 519-524

  Sciascia, Savino ^a   Mompean, Elisa ^b   Radin, Massimo ^a   Roccatello, Dario ^a   Cuadrado, Maria J ^b  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISONE;

AVASCULAR NECROSIS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG MEGADOSE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS, SYSTEMIC; META ANALYSIS; PSYCHOLOGY;

GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85016411766     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-017-0518-z     Document Type: Review

References (19)

1. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145–53.
2. Zahr ZA, Fang H, Magder L, Petri M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus. 2013;22:697–701.
3. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam L-S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–9.
4. Buttgereit F. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;1(61):718–22.
5. Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901–11.
6. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.
7. Barron KS, Person DA, Brewer EJ, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982;101:137–41.
8. Belmont HM, Kitsis E, Skovron ML, Buyon J, McCullagh E, Abramson S. Misoprostol and prednisone treatment of lupus nephritis. Am J Ther. 1995;2:928–32.
9. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (London, England). 1992;340:741–5.
10. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975;83(5):597–605.
11. Edwards JC, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis. 1987;46:773–6.
12. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–57.
13. MedCalc. Steroid Equivalence Converter [cited 2017 Mar 12]. Available from: http://www.medcalc.com/steroid.html.
14. Shimmer BP, Funder JW, et al. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s the pharmacological basis of therapeutics, Chapter 42, 12th edn. New York, USA: McGraw-Hill Companies; 2015. pp. 1202–25.
15. Buttgereit F, Straub RH, Wehling M, Burmester G-R. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408–17.
16. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–804.
17. Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14:1123–30.
18. Sciascia S, Talavera-Garcia E, Roccatello D, Baldovino S, Mengatti E, Cuadrado MJ. Upcoming biological therapies in systemic lupus erythematosus. Int Immunopharmacol. 2015;27:189–93.
19. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–8.